Leadership Team

Dr. Alisa Serio is Executive Director of Microbiology and Nonclinical Development at Paratek Pharmaceuticals, Inc. and has previously held positions in microbiology at Achaogen, Inc. Dr. Serio has over a decade of experience in antibacterial research and development, with a specific focus on combating antimicrobial resistance (AMR). She has contributed to the FDA approval and commercial launch of new antibiotics designed to evade AMR and lead research activities under several United States government partnerships including Biomedical Advanced Research and Development Authority (BARDA), Defense Threat Reduction Agency (DTRA) and National Institute of Allergy and Infectious Diseases (NIAID). She received her PhD in molecular biology and microbiology from Tufts University Graduate School of Biomedical Sciences and completed a postdoctoral fellowship in molecular and cell biology at the University of California, Berkeley, which was funded by the National Institutes of Health (NIH) and American Heart Association (AHA). Dr. Serio is a long-standing member of the American Society of Microbiology, Infectious Disease Society of America, and the European Society of Clinical Microbiology and Infectious Diseases.